Nvidia and TSMC to unveil first domestic wafer for Blackwell chips, Axios reports
Investing.com - Barclays initiated coverage on Tvardi Therapeutics Inc (NASDAQ:TVRD) with an Overweight rating and a $61.00 price target on Monday. According to InvestingPro data, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 4.04x.
The research firm highlighted Tvardi as a biopharmaceutical company focused on developing small molecule therapeutics for fibrosis-driven diseases, with its lead asset TTI-101 currently being evaluated for idiopathic pulmonary fibrosis (IPF).
Barclays noted that early data for TTI-101 suggests clinical benefits in a market where approved therapies Esbriet and Ofev collectively reached peak sales of approximately $5.4 billion despite having notable limitations.
The firm acknowledged that the upcoming data disclosure this quarter carries binary risks but expressed confidence in TTI-101’s potential based on its mechanism of action and data generated to date.
Barclays also pointed to additional growth potential for Tvardi Therapeutics through TTI-101’s development in hepatocellular carcinoma, which the firm views as "additional optionality" for the company. For deeper insights into TVRD’s financial health, growth metrics, and 13 additional ProTips, visit InvestingPro.
In other recent news, Tvardi Therapeutics announced the resignation of board member Shaheen Wirk. Dr. Wirk stepped down from the board on July 8, with the company clarifying that his departure was not due to any disagreements. He had joined the board in March 2024 after serving as a special advisor. Tvardi Therapeutics expressed gratitude for his contributions during his time with the company. Additionally, Raymond James has initiated coverage on Tvardi Therapeutics with an Outperform rating. The firm set a price target of $62.00, citing the company’s development of TTI-101, a promising oral small molecule inhibitor. This inhibitor targets STAT3, a key molecule linked to fibrosis and cancer. These developments highlight Tvardi Therapeutics’ ongoing strategic movements in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.